Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled time : 06:00 save search
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Published: 2024-03-26 (Crawled : 06:00) - globenewswire.com
DVAX | $12.03 1.6% 130K
|
Health Technology
|
| O: 0.72%
H: 0.4%
C: -1.75%
candidate vaccine valneva trial
New Novotech Report Finds 1,000 HIV Clinical Trials Globally
Published: 2023-12-29 (Crawled : 06:00) - biospace.com/
MEDE | $0.51 0% 500
|
n/a
| Email alert
Add to watchlist
report trials hiv
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
Published: 2023-11-02 (Crawled : 06:00) - globenewswire.com
MOLN | $3.88 390
|
Professional, Scientific, and T...
|
| O: 9.32%
H: 5.26%
C: 4.76%
mp0533 ongoing aml meeting trial molecular
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
Published: 2023-10-25 (Crawled : 06:00) - globenewswire.com
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: -0.69%
H: 4.18%
C: 3.59%
flt201 disease congress positive trial therapy
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
Published: 2023-10-23 (Crawled : 06:00) - globenewswire.com
NBTX | $5.73 850
|
Manufacturing
|
| O: 0.0%
H: 0.0%
C: -0.16%
cancer pancreatic trial results
ooma-blog-lead-form-business-30-days-trial
Published: 2023-10-19 (Crawled : 06:00) - ooma.com
OOMA 4 | $7.085 -0.07% 13K
|
Technology Services
|
| O: 0.24%
H: 0.24%
C: -3.01%
Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria
Published: 2023-08-09 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $95.11 490
|
Health Technology
|
| O: 1.11%
H: 0.53%
C: 0.53%
NVS | News | $98.12 3.15% 1.1M
|
Health Technology
|
| O: -0.07%
H: 0.73%
C: 0.36%
urticaria rapid control trials novartis
Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis
Published: 2023-07-13 (Crawled : 06:00) - prnewswire.com
HALO M | $39.04 0.85% 69K
|
Health Technology
|
| O: 0.97%
H: 5.14%
C: 4.42%
ocrevus drug positive sclerosis technology trial results
First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
Published: 2023-07-11 (Crawled : 06:00) - biospace.com/
SNY | News | $47.375 0.48% 300K
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
iph6401 trial
Christian Mingle free trial offer â 2 measures to Saving (No marketing Code)
Published: 2023-07-06 (Crawled : 06:00) - nxtenergy.com
NSFDF | $0.1212 12K
|
Industrial Services
| Email alert
Add to watchlist
free trial
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
Published: 2023-03-27 (Crawled : 06:00) - globenewswire.com
PFE | News A | $26.32 0.23% 4.4M
|
Health Technology
|
| O: 0.37%
H: 0.2%
C: -0.79%
NVS | News | $98.12 3.15% 1.1M
|
Health Technology
|
| O: 6.51%
H: 1.75%
C: 1.4%
kisqali breast cancer novartis trial
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer
Published: 2022-12-02 (Crawled : 06:00) - biospace.com/
URGN | $14.285 -0.59% 48K
|
Health Technology
|
| O: -1.49%
H: 3.84%
C: -2.44%
jelmyto treatment trial response cancer
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides
Published: 2022-09-23 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 5.45%
H: 0.0%
C: -8.46%
NVO | News | $127.41 1.72% 750K
|
Health Technology
|
| O: -0.53%
H: 0.81%
C: 0.14%
SNY | News | $47.375 0.48% 300K
|
Health Technology
|
| O: -1.69%
H: 0.0%
C: 0.0%
IPHA | $2.425 530
|
Health Technology
|
| O: -2.02%
H: 0.41%
C: -3.72%
ongoing pharma trial phase 2
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
Published: 2022-09-19 (Crawled : 06:00) - globenewswire.com
NVS | News | $98.12 3.15% 1.1M
|
Health Technology
|
| O: -0.52%
H: 0.69%
C: 0.62%
AMGN | News | $272.245 0.12% 220K
|
Health Technology
|
| O: -0.22%
H: 0.1%
C: 0.05%
biosimilar trial positive
Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China
Published: 2022-09-05 (Crawled : 06:00) - biospace.com/
ALPMY | News | $9.53 690K
|
Manufacturing
| Email alert
Add to watchlist
ALPMF | News | $9.75 200
|
Health Technology
| Email alert
Add to watchlist
topline china results study
Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial
Published: 2022-08-01 (Crawled : 06:00) - globenewswire.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: 46.2%
H: 13.2%
C: -2.0%
cyad-101 fda trial phase 2b clinical hold
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Published: 2022-07-14 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $47.375 0.48% 300K
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $908.53 0.93% 40K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results phase 3
Press Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial
Published: 2022-05-30 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.375 0.48% 300K
|
Health Technology
| Email alert
Add to watchlist
cialis trial
New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22)
Published: 2022-03-21 (Crawled : 06:00) - globenewswire.com
LXRX | $1.705 -0.29% 530K
|
Health Technology
|
| O: 0.46%
H: 2.5%
C: -1.36%
trial cardiovascular
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its RSV Vaccine Candidate in Older Adults
Published: 2022-04-20 (Crawled : 06:00) - globenewswire.com
JNJ | News | $148.24 -0.59% 1.6M
|
Health Technology
|
| O: 1.06%
H: 1.14%
C: 0.91%
vaccine trial phase 3 order
Gainers vs Losers
| 89% | 11% |
Top 10 Gainers
MTTR | News M | $4.65 167.24% 9.8M
|
AGBA | $2.355 88.4% 34M
|
Finance
EDBL | News | $6.94 84.57% 1.4M
|
CZOO | $8.77 75.75% 11M
|
VNRX | $0.84 40.0% 2.6M
|
Health Technology
OPRT | News | $3.01 33.78% 6.8M
|
Finance
MLEC | $1.81 29.29% 2M
|
n/a
CMAX | $4.12 28.35% 65K
|
Manufacturing
MTC | $2.0 28.21% 1.7M
|
Technology Services
PEGY | $0.0586 27.95% 130M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.